An observational study in Herpes Zoster, Dementia and Postherpetic Neuralgia (PHN), sponsored by China Medical University Hospital. Completed at 1 site in Taiwan. Open to participants aged 40 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by China Medical University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Herpes Zoster with a site in Taiwan — 1 open to participants now, 2 under way, 1 of them phase 3. Herpes Zoster · Taiwan.
Among the 13 studies in Herpes Zoster with a site in Taiwan, this one is the only one that started in 2015, is one of 3 observational ones, and was the 13th registered.
300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.
Browse Herpes Zoster studies →1 of the 13 studies in Herpes Zoster with a site in Taiwan is open now. Recruiting first, the newest first:
Inti Labs · Sites in Taiwan
Ages up to 38 · Women only · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 40 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2015.
This study's enrollment of 73,404 is above the median of 290 across 42 observational studies indexed under Herpes Zoster.
Median enrollment 2,458 across the 10 interventional studies, 26,976 across the 3 observational. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 4 most frequent:
China Medical University Hospital is the lead sponsor of 480 studies on the registry; 116 are open to participants now.
China Medical University Hospital has 1 study filed under Herpes Zoster — fewer than ten, so there is no comparison to draw.
1 of the studies in Herpes Zoster with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Herpes Zoster with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective observational cohort study uses de-identified electronic health record data from the TriNetX Global Collaborative Network to evaluate whether postherpetic neuralgia after herpes zoster is associated with an increased risk of incident dementia. Adults aged 40 to 120 years with incident herpes zoster between 1 October 2015 and 31 December 2024 are identified using diagnostic codes. Postherpetic neuralgia is defined by International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes B02.22 or B02.29 recorded between 90 and 365 days after the index herpes zoster date, and comparators have no such codes between 90 and 365 days after index. The primary analysis uses 1:1 propensity score matching and a 365-day landmark design, including only individuals alive and free of dementia at the landmark. Time-to-event analyses estimate hazard ratios for incident dementia and related outcomes.
Data source and study design This is a retrospective cohort study using de-identified electronic health record data accessed through the TriNetX platform. The primary analysis is conducted in the TriNetX Global Collaborative Network. Replication is performed in the TriNetX Asia Pacific (APAC) network as a geographic validation.
Population and index date Eligible individuals are aged 40 to 120 years and have an incident herpes zoster diagnosis (ICD-10-CM B02) recorded between 1 October 2015 and 31 December 2024, with a 3-year washout period free of herpes zoster before the index date. Baseline covariates are assessed up to 1 day before the index date.
Exposure definition Postherpetic neuralgia is defined by ICD-10-CM codes B02.22 or B02.29 recorded between 90 and 365 days after the index date. The comparator cohort includes individuals with incident herpes zoster and no record of B02.22 or B02.29 between 90 and 365 days after the index date. A prespecified stricter exposure definition requires at least two postherpetic neuralgia codes separated by at least 30 days.
Landmark design and follow-up The primary analysis uses a 365-day landmark after the index date. Only individuals alive and free of the specified outcome at the landmark enter the risk set. Follow-up starts at the landmark and continues until the first record of the outcome, death, or the last recorded fact in the patient's record, up to the date of data extraction.
Matching and analysis Cohorts are matched 1:1 using nearest neighbour propensity score matching with a caliper of 0.1. Balance is assessed using standardised mean differences. Time-to-event analyses use Kaplan-Meier methods and Cox proportional hazards models, reporting hazard ratios with 95% confidence intervals.
Outcomes The primary outcome is incident all-cause dementia defined by ICD-10-CM codes F01, F02, F03, or G30. Prespecified secondary outcomes include Alzheimer disease, vascular dementia, other or unspecified dementia, all-cause mortality, ischaemic stroke, and hip fracture. The Benjamini-Hochberg false discovery rate is applied to the six secondary outcomes only. A negative control outcome of acute appendicitis (ICD-10-CM K35) is included to assess residual bias.
Sensitivity and validation analyses Prespecified analyses include an alternative 730-day landmark, the stricter postherpetic neuralgia definition, additional adjustment for recorded zoster vaccination as a baseline covariate, and replication in the TriNetX APAC network using prespecified matching settings.
The study population comprises adults aged 40 to 120 years with incident herpes zoster identified in the TriNetX Global Collaborative Network from 1 October 2015 to 31 December 2024. Exposure groups are defined by the presence or absence of recorded postherpetic neuralgia diagnoses within 90 to 365 days after the index herpes zoster date. Follow-up for outcomes starts at a 365-day landmark after index among individuals alive and free of the outcome at the landmark. Replication analyses are performed in the TriNetX Asia Pacific (APAC) network.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 40 to 120 years with incident herpes zoster between 1 October 2015 and 31 December 2024 who had a recorded postherpetic neuralgia diagnosis (ICD-10-CM B02.22 or B02.29) between 90 and 365 days after the index herpes zoster date. Follow-up begins at a 365-day landmark after index among individuals alive and free of dementia at the landmark.
Other: Exposure: postherpetic neuralgia
Adults aged 40 to 120 years with incident herpes zoster between 1 October 2015 and 31 December 2024 with no recorded postherpetic neuralgia diagnosis (ICD-10-CM B02.22 or B02.29) between 90 and 365 days after the index herpes zoster date. Follow-up begins at a 365-day landmark after index among individuals alive and free of dementia at the landmark.
This is an observational study and no treatment is assigned by the investigators. The intervention of interest is exposure status defined by recorded diagnoses of postherpetic neuralgia after herpes zoster, based on ICD-10-CM codes B02.22 or B02.29 within 90 to 365 days after the index herpes zoster date.
Incident all-cause dementia
Incident all-cause dementia is identified using ICD-10-CM codes F01, F02, F03, or G30. Individuals with any record of dementia before the 365-day landmark are excluded from the risk set.
Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of dementia, death or the last recorded fact, up to the date of data extraction.
Alzheimer disease
Incident Alzheimer disease is identified using ICD-10-CM code G30. Individuals with any record of Alzheimer disease before the 365-day landmark are excluded from the risk set.
Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of Alzheimer disease, death or the last recorded fact, up to the date of data extraction.
Vascular dementia
Incident vascular dementia is identified using ICD-10-CM code F01. Individuals with any record of vascular dementia before the 365-day landmark are excluded from the risk set.
Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of vascular dementia, death or the last recorded fact, up to the date of data extraction.
Other or unspecified dementia
Incident other or unspecified dementia is identified using ICD-10-CM codes F02 or F03. Individuals with any record of these diagnoses before the 365-day landmark are excluded from the risk set.
Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of other or unspecified dementia, death or the last recorded fact, up to the date of data extraction.
All-cause mortality
All-cause mortality is identified using the death indicator available within the TriNetX network.
Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of death or the last recorded fact, up to the date of data extraction.
Ischaemic stroke
Incident ischaemic stroke is identified using ICD-10-CM code I63. Individuals with any record of ischaemic stroke before the 365-day landmark are excluded from the risk set.
Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of ischaemic stroke, death or the last recorded fact, up to the date of data extraction.
Hip fracture
Incident hip fracture is identified using ICD-10-CM codes S72.0, S72.1, or S72.2. Individuals with any record of hip fracture before the 365-day landmark are excluded from the risk set.
Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of hip fracture, death or the last recorded fact, up to the date of data extraction.
Acute appendicitis (negative control outcome)
Incident acute appendicitis is identified using ICD-10-CM code K35. Individuals with any record of acute appendicitis before the 365-day landmark are excluded from the risk set.
Time frame: From the 365-day landmark after the index herpes zoster date to the earliest of the first record of acute appendicitis, death or the last recorded fact, up to the date of data extraction.
Plan to share: No — Individual participant data (IPD) cannot be shared publicly because the TriNetX data are available only to subscribing organisations under licence agreements and governance controls. Investigators access de-identified records within the platform and are not permitted to download or redistribute line-level data. Researchers with access to TriNetX can reproduce the analysis using the cohort definitions and query parameters reported in the study.
Ran from Oct 2015 to primary completion in Oct 2026, 132 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Dec 2024 → Oct 2026 and completion Dec 2024 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China Medical University Hospital →